1.00Open1.60Pre Close86 Volume512 Open Interest250.00Strike Price10.94KTurnover621.93%IV1.64%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.1588Delta0.0669Gamma820.90Leverage Ratio-214.8559Theta0.0000Rho130.40Eff Leverage0.0014Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet